Tagged with takeda

Turkey Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer to global organisations, why the well-educated and cost-efficient domestic labour force is so important to the Turkish pharma market’s future,…

Japan Experienced global leader Takafumi Horii explains the rationale behind returning to his home nation of Japan to head up Takeda’s Japan Oncology operations. Horii also touches on the significant burden of cancer in Japan, how Takeda’s solutions help meet some of the country’s most significant unmet cancer needs, as well…

Turkey Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how the organization has seized on Takeda’s revamped portfolio, focusing on rare diseases, haematology, immunology, gastroenterology, and oncology, to move up…

Japan “This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey,” said Christophe Weber, Takeda’s CEO, after the USD 62 billion acquisition of international biotech Shire was completed in 2019. Two years later, the Japanese giant appears to finally be on…

Japan The latest from Japanese pharma, including Takeda’s big profit jump, British Linepharma’s quest to get the first ever induced abortion pill for practical use, Shionogi’s promise to become the first Japanese company to get a COVID-19 vaccine approved, and the Japanese industry’s opposition to the Biden administration’s support for a…

Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

Global While great strides in gender diversity has been made within healthcare boardrooms and leadership teams globally, as well as more generally across the workplace and many other arenas in many countries, at times we are served a stark reminder that the fight for greater gender equality and women representation is…

Global 2020 was a challenging year globally, but one in which the importance of the healthcare and life sciences sector was underlined like never before. Despite lockdowns and travel restrictions, PharmaBoardroom still managed to talk to key industry stakeholders from across the world helping shape the future of global health. Featured…

USA Rare disease – defined in the US as a disease with a maximum patient population of 200,000 – is perhaps the most salient issue at the nexus of innovation, access, and affordability in the country.   As FDA CDER director Dr Janet Woodcock indicates, “rare diseases have been rising as…

USA After five years with Takeda heading up the Japan-headquartered pharma company’s US business, following the organization’s 2019 USD 62 billion acquisition of US rare disease player Shire, Ramona Sequeira was appointed president of global portfolio commercialization and a member of Takeda’s global executive team in April 2020. In conversation with…

Switzerland PharmaBoardroom highlights three of the most enterprising and dynamic pharma affiliate country managers working in Switzerland today and their strategies for success in one of the world’s most innovative nations.   Henrik Asmussen, General Manager, Amgen Switzerland   Danish national Henrik Asmussen, head of Amgen Switzerland since 2017, outlined the…